Adverum Biotechnologies Announces Data Presentations at the European Society of Gene and Cell Therapy (ESGCT) Meeting
October 20 2016 - 8:00AM
Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a gene therapy company
committed to discovering and developing novel medicines for
patients suffering from diseases with few or burdensome treatment
options, announced today the presentation of preclinical data on
ADVM-022 and ADVM-032, the Company’s novel gene therapy candidates
for ophthalmology. The Company is presenting data during an oral
presentation and two poster sessions at the European Society of
Gene and Cell Therapy (ESGCT) meeting, held October 18 – 21, 2016
in Florence, Italy.
“Our lead ophthalmology gene therapy candidates ADVM-022 and
ADVM-032, with intravitreal administration, show compelling
proof-of-concept of these vectors’ anti-angiogenic effect in
laser-induced choroidal neovascularization. These data are
comparable to the anti-VEGFA standard of care when evaluated in a
model for the treatment of age-related macular degeneration,” said
Amber Salzman, Ph.D., President and Chief Executive Officer of
Adverum Biosciences. “Importantly, the side effect profile appears
manageable, with any moderate inflammation resolving by week 12 in
every instance, and no ocular adverse effect observed at 20 weeks
post injection. We are excited by the efficacy and safety
profile seen in this preclinical study and we are eager to initiate
toxicology studies in the first half of 2017 for ADVM-022 and
ADVM-032. We believe these therapies could have the potential
to alleviate patients from the burden of frequent injections in
managing their ocular disease.”
“Additionally, data are being presented that show the
baculovirus-derived AAV vector being virtually indistinguishable
from vector made in the mammalian hek293 system,” added Medhi
Gasmi, Ph.D., Chief Technology Officer and Interim Chief Scientific
Officer of Adverum Biosciences. “The baculovirus-based
manufacturing process is highly efficient and scalable, which is
key to delivering on our future clinical and commercial product
needs.”
Oral Presentation:Impact of vector design and
administration technique in gene therapy for the treatment of
age-related macular degenerationPresentation of preclinical data on
the intravitreal administration of Adverum’s gene therapy for
ophthalmology ADVM-022 (AAV.7m8-aflibercept) and ADVM-032
(AAV.7m8-ranibizumab)Presenter: Mehdi Gasmi,
Ph.D., Chief Technology Officer and Interim Chief Scientific
Officer, Adverum BiotechnologiesDate/Time: Thursday, October 20,
2016, Session 5C, 2:00 - 4:00 pm CET
Poster Presentations:Evaluating the degree of
HSPG-binding for effective AAV transduction following intravitreal
administrationPresenter: Annahita Keravala, Ph.D., Director Novel
Vector Technology, Adverum BiotechnologiesDate/Time: Wednesday,
October 19, 2016, 6:30 - 8:30 pm CET
A highly scalable baculovirus-based process to manufacture AAV
vector of various serotypesPresenter: Mehdi Gasmi, Ph.D., Chief
Technology Officer and Interim Chief Scientific Officer,
Adverum BiotechnologiesDate/Time: Wednesday, October 19, 2016, 6:30
- 8:30 pm CET
About Adverum Biotechnologies,
Inc.Adverum is a gene therapy company committed to
discovering and developing novel medicines that can
offer life-changing benefits to patients living with rare
diseases or diseases of the eye who currently have limited or
burdensome treatment options. Adverum has a
robust pipeline that includes product candidates to treat wet AMD,
A1AT deficiency, and hereditary angioedema, among others. We
are leveraging our next-generation adeno-associated virus
(AAV)-based directed evolution platform to generate product
candidates designed to provide durable efficacy by inducing
sustained expression of a therapeutic protein. Our focus on
the patient is supported by clinical development expertise and core
capabilities in vector optimization, process development,
manufacturing, and assay development. For more information
please visit www.adverumbio.com.
Forward-Looking Statements for Adverum
Biotechnologies Statements contained in this press release
regarding matters that are not historical facts are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Such statements include,
but are not limited to, statements regarding Adverum’s plans,
potential opportunities, expectations, projections, goals,
objectives, milestones, strategies, product pipeline, the
sufficiency of its resources to fund the advancement of any
development program or the completion of any clinical trials, and
the safety, efficacy, and projected development timeline and
commercial potential of products under development, all of which
are based on certain assumptions made by us on current conditions,
expected future developments and other factors we believe are
appropriate in the circumstances. Adverum may not consummate any
plans or product development goals in a timely manner, or at all,
or otherwise carry out the intentions or meet the expectations or
projections disclosed in our forward-looking statements, and you
should not place undue reliance on these forward-looking
statements. Actual results and the timing of events could differ
materially from those anticipated in such forward-looking
statements as a result of various risks and uncertainties, which
include, without limitation, the risk that Adverum’s resources will
not be sufficient for Adverum to conduct or continue planned
development programs, the risk that the results of preclinical
studies will not be indicative of the results of future studies and
clinical trials, if any, the risk of a delay in the manufacturing
of products to be used in any clinical studies, risks related to
Adverum’s ability to obtain and maintain regulatory approvals, and
the risk that Adverum will not be able to successfully develop or
commercialize any of its product candidates. Risks and
uncertainties facing Adverum are described more fully in Adverum’s
periodic reports filed with the SEC. All forward-looking statements
contained in this press release speak only as of the date on which
they were made. Adverum undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made.
Contact for Adverum:
Tricia Truehart
Vice President
The Trout Group LLC
646-378-2953
ttruehart@troutgroup.com
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From Apr 2023 to Apr 2024